Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AbbVie will pay I-Mab $200 million now and up to $1.74 billion in milestone payments in the future for an exclusive license to commercialize lemzoparlimab…
AbbVie has entered into a global collaboration agreement with I-Mab to develop and commercialise lemzoparlimab (TJC4), an immuno-oncology therapy targeting…
AbbVie's $2.94 billion licensing deal with I-Mab for lemzoparlimab, a CD47 antibody, reflected the intense competitive interest in checkpoint inhibitor…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AbbVie entered an exclusive worldwide license agreement with I-Mab for lemzoparlimab (TJC4), an anti-CD47 monoclonal antibody designed to avoid red blood cell binding. AbbVie received global rights to develop and commercialize lemzoparlimab. I-Mab received $200M upfront and is eligible for up to $2.74B in development, regulatory, and commercial milestones plus tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / I-Mab (this deal) | 2020 | $2.9B | 26 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2020 deals · AbbVie Inc. deals · Oncology deals